<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Major side effects of low-dose methotrexate</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Major side effects of low-dose methotrexate</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Major side effects of low-dose methotrexate</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joel M Kremer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) use can be associated with a variety of adverse effects over a wide range of severity; the risk of most side effects is influenced by the MTX dose and treatment regimen. In rheumatoid arthritis (RA) and other disorders, MTX is administered as long-term, low-dose therapy, usually 7.5 to 25 mg weekly, unlike its use for treatment of malignant disease, where it may be administered in a cyclic fashion in doses of 1 gram or more.</p><p>The most commonly observed side effects of MTX at doses typically used for the treatment of RA are rarely life-threatening, in contrast with the high doses used in the treatment of malignancies. Nevertheless, they may become clinically significant if they result in premature discontinuation or dose alteration of a drug that is the best therapeutic alternative for a given individual.</p><p>Potentially life-threatening hepatotoxicity, pulmonary damage, and myelosuppression may be seen with use of MTX as either high- or low-dose therapy, while nephrotoxicity is a manifestation of high-dose therapy that occurs rarely, if ever, with low-dose MTX treatment.</p><p>The major side effects of low-dose MTX are reviewed here. The use of low-dose MTX in patients with RA and other rheumatic diseases and the clinical use and adverse effects of high-dose MTX and related adverse effects are described separately. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a>.)</p><p class="headingAnchor" id="H59543899"><span class="h1">COMMON TOXICITIES</span></p><p class="headingAnchor" id="H59544102"><span class="h2">Symptoms and findings</span><span class="headingEndMark"> — </span>One or more of the following common toxicities associated with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) are seen in some form, at some time, in most patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal problems, such as nausea, stomach upset, and loose stools</p><p class="bulletIndent1"><span class="glyph">●</span>Stomatitis or soreness of the mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal liver chemistries, which are typically mild elevations in hepatic transaminases (see <a class="local">'Hepatotoxicity'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>A macular punctate cutaneous eruption, which usually occurs on the extremities, often affecting the elbows and knees, but sparing the trunk</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system symptoms, including headache, fatigue, malaise, or impaired ability to concentrate</p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia</p><p class="bulletIndent1"><span class="glyph">●</span>Fever, which is drug-related, although fever can also occur due to infection </p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic abnormalities, particularly macrocytosis, in addition to infrequent but severe myelosuppression (see <a class="local">'Myelosuppression'</a> below)</p><p></p><p>Central nervous system and gastrointestinal complaints commonly occur within 24 to 48 hours after the weekly MTX dose. However, alopecia can develop within weeks and is not generally dose related. Macrocytosis may take many months to develop; it should not always be assumed to be due to folate deficiency, as patients on MTX are typically receiving daily folate supplementation; it may instead be from an unrelated cause (eg, due to vitamin B12 deficiency) or can occur on MTX with normal serum levels of both folate and vitamin B12. Rash may appear within days of each weekly MTX dose and fade by the time of the next week's dose. On the other hand, stomatitis may persist for days or weeks; it can be mild or, on occasion, painful enough to make eating difficult and result in a desire to discontinue therapy.</p><p class="headingAnchor" id="H59544108"><span class="h2">Management</span><span class="headingEndMark"> — </span>Most of the common toxicities of MTX can be managed symptomatically, but patients with persistent symptoms sometimes require MTX dose reduction.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nausea</strong> – Patients who continue to have nausea associated with MTX administration may get some relief with a histamine H2 blocker (eg, <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 10 to 20 mg orally) or a proton pump inhibitor (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> 20 to 40 mg orally). These drugs are usually cycled in a weekly manner with MTX, being used the evening before, the day of, and the morning after the weekly MTX dose. Patients with nausea and other gastrointestinal symptoms also benefit from daily <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation. Nausea may also be improved by increasing the dose of daily folic acid up to 3 to 5 mg or adding <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (folinic acid) 8 to 10 hours after the weekly MTX dose. (See <a class="local">'Prevention of side effects with folate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stomatitis</strong> – In patients with mild to moderate stomatitis, we gradually increase the <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> dose from 1 mg daily up to 2 mg or higher (to a maximum of 5 mg daily) by 1 mg increments until the toxicity is controlled (see <a class="local">'Prevention of side effects with folate'</a> below). In patients without an adequate response and continued bothersome symptoms despite taking 5 mg daily, we add <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>. In patients in whom the combination of folate and leucovorin is inadequate, we gradually reduce the MTX dose to determine if a lower dose will be tolerated. Patients presenting with severe oral ulcers may require both a lowering of the MTX dose and an increase of folic acid. Once the acute toxicity has resolved, the patient may be able to increase the weekly dose of MTX back to the level being used prior to the onset of the oral ulcers. A recent decrement in renal function should also be excluded as a contributing factor.</p><p></p><p class="bulletIndent1">Stomatitis (oral mucositis) can occur at any dose of MTX but is more likely to be seen at higher doses. Data regarding the usefulness of supplements of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> or <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> are mixed. A systematic review in 1998 of folic acid or leucovorin supplementation concluded that these agents reduced the risk of stomatitis and other disorders of the digestive tract [<a href="#rid1">1</a>]. However, no difference in the proportion of patients developing mucositis (15 to 18 percent) or diarrhea (8 to 14 percent) were noted in a subsequent randomized trial in 434 patients that compared folic acid, leucovorin, and placebo [<a href="#rid2">2</a>]. Nevertheless, if a patient is not receiving folate supplementation, addition of folic acid or leucovorin may speed healing. (See  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy", section on 'Mucositis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal liver chemistries</strong> – The monitoring of liver chemistries and the management of patients with abnormalities in these tests are described in detail separately. (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease", section on 'Approach to monitoring in rheumatoid arthritis'</a>.)<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rash</strong> – We reduce the MTX dose in patients with the infrequent manifestation of a cutaneous eruption from MTX, but discontinue the medication in patients who do not respond to dose reduction, as the rash may represent a hypersensitivity reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurotoxicity</strong> – Symptoms such as severe headaches, fatigue, and problems concentrating may require dose reduction, and in some patients will require drug discontinuation. The mechanism by which these occur is uncertain; it has been suggested that the neurotoxicity of MTX may be related to the accumulation of adenosine due to the inhibition of purine synthesis [<a href="#rid3">3-5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever</strong> – Fever can be induced by MTX, but it is important to exclude infection as the cause before attributing this finding to MTX alone. Infections with <em>Pneumocystis jirovecii</em> (formerly termed <em>Pneumocystis carinii</em>) and fungi can occur; herpes zoster is rare, in contrast to its more frequent occurrence with glucocorticoids, tumor necrosis factor (TNF) inhibitors, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, Janus kinase inhibitors, or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic abnormalities</strong> – We withhold MTX in patients in whom the mean corpuscular volume (MCV) increases to about 110 microm<sup>3</sup>, based upon our clinical experience. This approach is supported by observations in a case series that sustained elevation in the MCV may be a predictor of hematologic toxicity due to folate depletion [<a href="#rid6">6</a>]. However, these observations have not been routinely confirmed in clinical practice. Thrombocytopenia and leukopenia or anemia are managed by dose reduction, but may require discontinuation of therapy depending upon their severity. </p><p></p><p class="headingAnchor" id="H59544302"><span class="h1">POTENTIAL SEVERE ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>Hepatotoxicity due to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) may result from direct damage to hepatocytes; or, in patients with concomitant viral hepatitis, MTX may enhance viral damage. Minor elevations in aminotransferases are common, but hepatic steatosis, fibrosis, and cirrhosis may infrequently occur. Hepatotoxicity associated with chronic low-dose MTX is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a> and  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p>Severe hepatotoxicity is very uncommon in patients managed using appropriate prevention strategies (see  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>). These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Screening before initiating long-term MTX therapy for hepatitis B and hepatitis C virus infection. In patients with infection, this should inform a decision whether to avoid the use of MTX, to try to eradicate the viral infection before initiating therapy, or to suppress viral replication during immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periodic monitoring of aminotransaminases and albumin. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Drug monitoring and prevention of drug toxicity'</a> and  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease", section on 'Approach to monitoring in rheumatoid arthritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine use of daily <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation, which is associated with a reduced risk of hepatic transaminase elevations. (See <a class="local">'Prevention of side effects with folate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling of patients to avoid or minimize alcohol intake while on MTX, although the amount of alcohol intake which might be safe while using MTX has not been formally evaluated. Some patients will tolerate daily alcohol, and some will not. (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Particular caution regarding the use of MTX is also warranted in the setting of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease", section on 'Pretreatment evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Pulmonary toxicity</span><span class="headingEndMark"> — </span>Pulmonary toxicity of MTX is seen with both high- and low-dose treatment and may present with acute or chronic symptoms. It is more common during the first year of treatment [<a href="#rid7">7</a>]. Either symptomatic or asymptomatic radiographic lung damage may be due to inflammation, infection, or MTX-related neoplasia. We and most other experts usually obtain a baseline chest radiograph prior to initiating MTX treatment, if one has not been recently obtained [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/d/html/4372.html" rel="external">"Methotrexate-induced lung injury", section on 'Prevention'</a>), although some experts do not do so in individuals perceived clinically to be at low risk of established pulmonary disease. Pulmonary toxicity, including its pathogenesis, prevention, manifestations, evaluation, and management, is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p class="headingAnchor" id="H59547426"><span class="h2">Risk of infection</span><span class="headingEndMark"> — </span>MTX is an immunomodulatory but not significantly immunosuppressive agent in the doses used for rheumatoid arthritis (RA) [<a href="#rid9">9</a>]; it is not associated with opportunistic infections in the overwhelming majority of those treated with MTX unless the patients are also being treated with high-dose glucocorticoids, other immunosuppressive disease-modifying antirheumatic drugs (DMARDs), or biologic agents. MTX can affect T cell activity in the weekly doses used in the treatment of rheumatic diseases [<a href="#rid10">10,11</a>], and cases of <em>Pneumocystis</em> pneumonia have been reported [<a href="#rid12">12,13</a>]. MTX can also increase risk of lymphoproliferative disease. (See <a class="local">'Risk of lymphoproliferative disorders'</a> below.)</p><p>In patients with severe infections (eg, pneumonia requiring hospitalization), we hold the MTX dose until the patient has recovered from the illness. We do not withhold therapy in patients with minor infections (eg, pharyngitis or a urinary tract infection treated with a short course of oral antibiotics).</p><p class="headingAnchor" id="H4"><span class="h2">Myelosuppression</span><span class="headingEndMark"> — </span>Myelosuppression is the major dose-limiting side effect of high-dose MTX, but is infrequent in patients receiving low-dose therapy. With low-dose weekly therapy, as used in RA, hematologic toxicity in association with macrocytic red blood cells may be seen [<a href="#rid6">6</a>], but a more serious abnormality is the development of pancytopenia [<a href="#rid14">14</a>]. Occasionally, anemia, leukopenia, or thrombocytopenia may occur without significant reductions in other cell lines. To prevent these complications, guidelines from the American College of Rheumatology (ACR) recommend that a routine peripheral complete blood count should be performed every four weeks during the first three months of therapy, every 8 to 12 weeks from three to six months, and every 8 to 12 weeks thereafter, depending upon the nature and/or severity of abnormalities noted during monitoring [<a href="#rid15">15</a>].</p><p>Myelosuppression with low-dose MTX is more likely if renal function is impaired (eg, in the setting of an acute illness or addition or change of a nonsteroidal antiinflammatory drug [NSAID]) or if MTX is taken daily instead of weekly. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Pharmacology'</a>.)</p><p class="headingAnchor" id="H59546082"><span class="h2">Risk of lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Lymphoproliferative disorders occur with increased frequency in RA, independent of specific therapies, but MTX therapy may increase such risk. Data from a large observational cohort (the National Data Bank for Rheumatic Diseases) found a small increase, based upon patient reports, which was not statistically significant (standardized incidence ratio of 1.7, 95% CI 0.9-3.2) [<a href="#rid16">16</a>]. Rarely, lymphoproliferative “malignancies” may develop after long-term therapy but regress spontaneously after MTX is withdrawn. They are usually of B-cell origin and some are associated with latent Epstein Barr virus infection [<a href="#rid17">17</a>]. Lymphoproliferative disorders in RA are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7505.html" rel="external">"Disease outcome and functional capacity in rheumatoid arthritis", section on 'Lymphoproliferative disorders'</a>.)</p><p>One prospective study described 25 cases of lymphoma in patients with RA who were being treated with MTX throughout France over a three-year period. Among these were seven cases of Hodgkin disease (27.8 and 2.8 cases per 100,000 per year for males and females respectively), an incidence that was more than expected for an age- and sex-matched population (adjusted standardized incidence ratio [SIR] of 7.4) [<a href="#rid18">18</a>]. The incidence of non-Hodgkin lymphoma was not increased by MTX therapy. Chemotherapy should be withheld until MTX has been stopped, since some of these tumors regress within four weeks after MTX has been discontinued [<a href="#rid19">19-22</a>]. Continued vigilance is necessary in those who regress, since relapse has occurred [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/7505.html" rel="external">"Disease outcome and functional capacity in rheumatoid arthritis", section on 'Lymphoproliferative disorders'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Nephrotoxicity</span><span class="headingEndMark"> — </span>Significant nephrotoxicity due to MTX may occur with use of high doses, but occurs very rarely, if at all, in patients on low-dose regimens. However, even at the low weekly doses used in rheumatic diseases, MTX use may be associated with slight decreases in creatinine clearance [<a href="#rid23">23</a>]. MTX is primarily cleared via the kidneys, with 80 to 90 percent being excreted unchanged in the urine. Thus, impaired renal excretion of the administered MTX and consequent prolonged exposure to the drug increase the risk of myelosuppression and other toxicities. <a class="drug drug_general" data-topicid="9048" href="/d/drug information/9048.html" rel="external">Glucarpidase</a> (carboxypeptidase G2), a recombinant bacterial enzyme that cleaves MTX into inactive metabolites, speeds clearance, and may be used when impaired renal function causes delayed elimination of MTX in patients receiving high-dose MTX. Its role in patients who develop renal toxicity while receiving chronic low-dose therapy is unclear. MTX-induced renal failure and the use of glucarpidase in the management of this complication are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury", section on 'Methotrexate'</a> and  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Glucarpidase (carboxypeptidase G2)'</a>.)</p><p>Kidney damage due to precipitation of MTX crystals and tubular injury may occur with high-dose MTX; it is very rare with chronic low-dose therapy. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Renal toxicity'</a>.)</p><p class="headingAnchor" id="H59546332"><span class="h2">Pregnancy risk</span><span class="headingEndMark"> — </span>MTX is an abortifacient that can also induce congenital anomalies if taken during pregnancy. It is therefore contraindicated in pregnant individuals. We advise contraceptive use in females taking MTX as well as discontinuation of therapy in both females and males at least three months prior to conception. Oligospermia and chromatid breaks have been described in males on MTX. However, many male patients taking weekly MTX have successfully had healthy children. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a> and  <a class="medical medical_review" href="/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H59546655"><span class="h1">OTHER ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H59546661"><span class="h2">Nodulosis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) has been demonstrated to exacerbate rheumatoid nodule formation (accelerated nodulosis) in some patients with rheumatoid arthritis (RA), despite the effective suppression of synovial inflammation [<a href="#rid24">24</a>]. This activity may be mediated via the agonist stimulation of adenosine A1 receptors by MTX, thereby leading to enhanced giant cell formation [<a href="#rid25">25</a>]. Rheumatoid nodules and the management of accelerated nodulosis associated with MTX are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7523.html" rel="external">"Rheumatoid nodules"</a> and  <a class="medical medical_review" href="/d/html/7523.html" rel="external">"Rheumatoid nodules", section on 'Methotrexate-induced accelerated nodulosis'</a>.)</p><p class="headingAnchor" id="H59546735"><span class="h2">Others</span><span class="headingEndMark"> — </span>Additional potential adverse effects of MTX include:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin cancer risk – A limited amount of evidence has suggested that MTX use in patients with RA or psoriatic arthritis may be associated with an increased risk of melanoma and non-melanoma skin cancers, but the number of cases in most studies have been small [<a href="#rid26">26-29</a>]. Additional data that further support an association of MTX with skin cancer come from a randomized trial comparing MTX (15 to 20 mg weekly) with placebo, designed to examine MTX for the prevention of cardiovascular events in patients with established coronary artery disease, in which an incidental finding was the greater incidence of non-basal-cell skin cancers in patients receiving MTX (31 versus 10 cases, rate ratio 3.08, p = 0.002) [<a href="#rid30">30</a>]. Strengths of the trial included its relatively large size, involving 4786 patients, and median follow-up of 2.3 years, longer than most randomized trials involving MTX. Further study of this association is warranted to confirm these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired response to vaccination – Use of MTX may interfere with the response to pneumococcal vaccine when used alone or in combination with the anti-tumor necrosis factor (TNF)-alpha agent <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, as well as the response to other vaccines [<a href="#rid31">31-34</a>]. It may be best to withhold two weekly doses of MTX when vaccines are administered. To the best of our knowledge, the effects of MTX on coronavirus disease 2019 (COVID-19) vaccines have not been formally studied. Immunization in patients receiving low-dose MTX is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Immunizations'</a> and  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular changes – MTX only rarely affects the eye; reported adverse effects include periorbital edema, pain, blurred vision, photophobia, blepharitis, conjunctivitis, and optic neuropathy related to folate deficiency [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone abnormalities with high-dose MTX – High-dose MTX regimens (such as those used for osteosarcoma or acute lymphoblastic leukemia) are associated with an increase in bone resorption and inhibition of bone formation, possibly resulting in both osteoporosis and fractures [<a href="#rid36">36,37</a>]. However, this has only rarely been observed with MTX in the dose range used for rheumatic disease [<a href="#rid38">38-41</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">PREVENTION OF SIDE EFFECTS WITH FOLATE</span><span class="headingEndMark"> — </span>We administer <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation on a daily basis in patients taking chronic low-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) to reduce risk of several common MTX toxicities and the likelihood of treatment discontinuation. The use of folic acid and of <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> in this setting is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Folic acid supplementation'</a>.)</p><p class="headingAnchor" id="H2231871670"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>One or more of the common toxicities associated with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) may be seen at some time in most patients. These include gastrointestinal problems such as nausea, stomach upset, and loose stools; stomatitis or soreness of the mouth; a macular punctate rash that usually occurs on the extremities and that spares the trunk; central nervous system problems including headache, fatigue, or impaired ability to concentrate; alopecia; fever; and hematologic abnormalities, particularly macrocytosis. (See <a class="local">'Common toxicities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatotoxicity due to MTX may result from direct damage to hepatocytes; or, in patients with concomitant viral hepatitis, MTX may enhance viral damage. Patients should be screened for hepatitis before beginning therapy and should be monitored for toxicity regularly while receiving the drug. (See <a class="local">'Hepatotoxicity'</a> above and  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary toxicity of MTX may present with acute or chronic symptoms and is more common in the first year of treatment. Either symptomatic or asymptomatic radiographic lung damage may be due to inflammation, infection, or MTX-related pneumonitis. We usually obtain a baseline chest radiograph before initiating MTX treatment. (See <a class="local">'Pulmonary toxicity'</a> above and  <a class="medical medical_review" href="/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic toxicity of low-dose weekly therapy includes red blood cell macrocytosis and, less often, anemia, thrombocytopenia, or leukopenia. Pancytopenia is very uncommon. Patients receiving MTX should be monitored periodically with a complete blood count and platelet count. Myelosuppression with low-dose MTX is more likely if renal function is impaired in the setting of an acute illness or addition or change of a nonsteroidal antiinflammatory drug (NSAID). MTX may also increase the risk of lymphoproliferative malignancy in patients with rheumatoid arthritis (RA). (See <a class="local">'Myelosuppression'</a> above and <a class="local">'Risk of lymphoproliferative disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impairment of glomerular filtration rate will result in sustained serum levels of the drug that may induce bone marrow or other toxicities, because it is primarily cleared unchanged through the kidneys. Kidney damage due to precipitation of MTX crystals and tubular injury may occur with high-dose MTX, but it is very rare with chronic low-dose therapy. (See <a class="local">'Nephrotoxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional adverse effects include exacerbation of rheumatoid nodulosis; marked adverse effects upon the fetus during pregnancy, which should be avoided while on MTX; diminished vaccine responses; and rare ocular abnormalities. (See <a class="local">'Nodulosis'</a> above and <a class="local">'Pregnancy risk'</a> above and <a class="local">'Others'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In all patients taking low-dose MTX on a chronic basis, we recommend treatment with <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> (1 mg daily) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). The dose may be increased up to 5 mg/day as needed, based upon reporting of residual symptoms. <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">Leucovorin</a> should only be used in patients who have not had a satisfactory response to folic acid (ie, toxicities remain). (See <a class="local">'Prevention of side effects with folate'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25:36.</a></li><li><a class="nounderline abstract_t">van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44:1515.</a></li><li><a class="nounderline abstract_t">Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:9.</a></li><li><a class="nounderline abstract_t">Quinn CT, Kamen BA. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996; 44:522.</a></li><li><a class="nounderline abstract_t">Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995; 345:544.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32:1592.</a></li><li><a class="nounderline abstract_t">Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40:1829.</a></li><li><a class="nounderline abstract_t">Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127:356.</a></li><li><a class="nounderline abstract_t">Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951.</a></li><li><a class="nounderline abstract_t">Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322.</a></li><li><a class="nounderline abstract_t">O'Meara A, Headon B, Reen DJ. Effect of methotrexate on the immune response in children with acute lymphatic leukaemia. Immunopharmacology 1985; 9:33.</a></li><li><a class="nounderline abstract_t">Kaneko Y, Suwa A, Ikeda Y, Hirakata M. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. Mod Rheumatol 2006; 16:36.</a></li><li><a class="nounderline abstract_t">Stenger AA, Houtman PM, Bruyn GA, et al. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J Rheumatol 1994; 23:51.</a></li><li><a class="nounderline abstract_t">Gutierrez-Ureña S, Molina JF, García CO, et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39:272.</a></li><li><a class="nounderline abstract_t">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a class="nounderline abstract_t">Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50:1740.</a></li><li><a class="nounderline abstract_t">Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol 2000; 113:212.</a></li><li><a class="nounderline abstract_t">Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002; 99:3909.</a></li><li><a class="nounderline abstract_t">Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317.</a></li><li><a class="nounderline abstract_t">Bachman TR, Sawitzke AD, Perkins SL, et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 1996; 39:325.</a></li><li><a class="nounderline abstract_t">Moseley AC, Lindsley HB, Skikne BS, Tawfik O. Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease. J Rheumatol 2000; 27:810.</a></li><li><a class="nounderline abstract_t">Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol 2014; 41:293.</a></li><li><a class="nounderline abstract_t">Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22:38.</a></li><li><a class="nounderline abstract_t">Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29:822.</a></li><li><a class="nounderline abstract_t">Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 1997; 40:1308.</a></li><li><a class="nounderline abstract_t">Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol 2010; 37:2205.</a></li><li><a class="nounderline abstract_t">Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014; 43:489.</a></li><li><a class="nounderline abstract_t">Lange E, Blizzard L, Venn A, et al. Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford) 2016; 55:1594.</a></li><li><a class="nounderline abstract_t">Scott FI, Mamtani R, Brensinger CM, et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016; 152:164.</a></li><li><a class="nounderline abstract_t">Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med 2019; 380:752.</a></li><li><a class="nounderline abstract_t">Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014; 66:1016.</a></li><li><a class="nounderline abstract_t">Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2017; 76:1559.</a></li><li><a class="nounderline abstract_t">Bitoun S, Nocturne G, Ly B, et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis 2018; 77:1463.</a></li><li><a class="nounderline abstract_t">Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018; 77:898.</a></li><li><a class="nounderline abstract_t">Peponis V, Kyttaris VC, Chalkiadakis SE, et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus 2010; 19:675.</a></li><li><a class="nounderline abstract_t">Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18:1570.</a></li><li><a class="nounderline abstract_t">Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11:13.</a></li><li><a class="nounderline abstract_t">Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24:1489.</a></li><li><a class="nounderline abstract_t">Ide M, Suzuki Y, Ichikawa Y, et al. Influence of long-term low-dose methotrexate therapy on periarticular and generalized osteoporosis in rheumatoid arthritis. Jap J Rheumatol 1999; 9:75.</a></li><li><a class="nounderline abstract_t">Preston SJ, Diamond T, Scott A, Laurent MR. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52:582.</a></li><li><a class="nounderline abstract_t">Rolvien T, Creutzfeldt AM, Lohse AW, Amling M. Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy. Lupus 2019; 28:790.</a></li></ol></div><div id="topicVersionRevision">Topic 7509 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458200" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11465701" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405864" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9035605" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aminophylline for methotrexate-induced neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2597212" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9336418" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9273826" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961899" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular therapeutics. Methotrexate and its mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9664073" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3857220" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of methotrexate on the immune response in children with acute lymphatic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622722" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8108669" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849378" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512708" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188349" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10664623" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010788" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8385742" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849387" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10743830" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334644" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7699678" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3741499" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214432" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810498" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012043" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27185957" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26510126" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415610" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339395" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of methotrexate, anti-tumor necrosis factorα, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28468794" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29936438" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Methotrexate and BAFF interaction prevents immunization against TNF inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572291" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20144965" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ocular side effects of anti-rheumatic medications: what a rheumatologist should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735906" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Osteoporosis due to cancer treatment: pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6424236" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Methotrexate osteopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9263140" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Influence of long-term low-dose methotrexate therapy on periarticular and generalized osteoporosis in rheumatoid arthritis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215620" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Methotrexate osteopathy in rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947618" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
